5 Key Takeaways

• 1

  The FDA approved Glaukos' NDA supplement for repeat use of iDose® TR, enhancing treatment options for glaucoma patients.

• 2

  iDose TR is a long-duration, intracameral therapy that delivers continuous therapeutic levels of travoprost.

• 3

  The approval is based on clinical evidence supporting the safety and tolerability of iDose TR's repeat administration.

• 4

  Physicians can re-administer iDose TR in patients with a healthy cornea, as defined by endothelial cell density.

• 5

  Clinical studies show iDose TR maintains a favorable corneal safety profile with no significant cell loss over three years.